Wyeth/Aviron FluMist
Executive Summary
Nasal influenza vaccine will be reviewed by Vaccines & Related Biological Products Advisory Committee during July 26-27 meeting. The companies are seeking an indication for use in healthy children and adults. "We are hopeful about getting on the market this year, but obviously that requires FDA approval, and I think especially today, it's difficult to make firm projections about when this vaccine will be approved," AHP Chief Operating Officer Robert Essner said during an April 25 conference call. FluMist BLA was submitted Oct. 30